
Adragosrevenue & acquisition
Munich, Bavaria, GermanyFounded 2020
Adragos was acquired.
Adragos Pharma is a globally operating Contract Development and Manufacturing Organisation (CDMO) focused on the development and manufacturing of drug products (FDF) in the small molecule segment.
Adragos revenue
Adragos has not published its revenue. Growjo puts it at about $74.6M a year (September 2024).
$0
$20M
$40M
$60M
$0
–
$74.6M
20202021–232024
| As of | Revenue | Source |
|---|---|---|
| Sep 2024 | $74.6MEST | Growjo estimate |
Who owns Adragos
Another company owns Adragos. The date and price of the deal are not on record.
Adragos team
- Henny ZijlstraChief Commercial Officer
Categories
How this page is sourced
1 estimate. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Oct 14, 2026Data disclaimerReport a correctionClaim this profileRun Adragos? Join the podcast